Trials / Completed
CompletedNCT01206777
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Ohio State University Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the feasibility of a 60 minute rapid infusion rituximab protocol in the institution's outpatient infusion center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2010-09-22
- Last updated
- 2017-12-20
- Results posted
- 2015-02-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01206777. Inclusion in this directory is not an endorsement.